Protective role of sulphoraphane against vascular complications in diabetes

Pharmaceutical Biology

Volumn 54, Issue 10, 2016, Pages 2329-2339

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; cardiovascular disease; diabetic angiopathy; oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ISOTHIOCYANIC ACID; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, HUMAN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ISOTHIOCYANIC ACID DERIVATIVE; NFE2L2 PROTEIN, HUMAN; SULFORAFAN; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AORTA; BLOOD PRESSURE; BLOOD VESSEL INJURY; BROCCOLI; BRUSSELS SPROUT; CABBAGE; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CELL CULTURE; CONTROLLED STUDY; DETOXIFICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISABILITY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLYCATION; IN VITRO STUDY; INFLAMMATION; KIDNEY FAILURE; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PROSPECTIVE STUDY; RAT; REVIEW; RISK REDUCTION; VASCULAR SMOOTH MUSCLE CELL; VEGETABLE; ANIMAL; DIABETIC ANGIOPATHIES; DRUG EFFECTS; HUMAN; MEDICINAL PLANT; METABOLISM; PHYTOTHERAPY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ISOTHIOCYANATES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PHYTOTHERAPY; PLANTS, MEDICINAL;

EID: 84958537581     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2016.1138314     Document Type: Review

References (101)

1. C.Angeloni, M.Malaguti, B.Rizzo, M.C.Barbalace, D.Fabbri, S.Hrelia. 2015. Neuroprotective effect of sulforaphane against methylglyoxal cytotoxicity. Chem Res Toxicol. 28:1234–1245.
2. M.Asakage, N.H.Tsuno, J.Kitayama, T.Tsuchiya, S.Yoneyama, J.Yamada, Y.Okaji, S.Kaisaki, T.Osada, K.Takahashi,. 2006. Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis. Angiogenesis 9:83–91.
3. B.Annabi, S.Rojas-Sutterlin, M.Laroche, M.P.Lachambre, R.Moumdjian, R.Béliveau. 2008. The diet-derived sulforaphane inhibits matrix metalloproteinase-9-activated human brain microvascular endothelial cell migration and tubulogenesis. Mol Nutr Food Res. 52:692–700.
4. M.Bäck, G.K.Hansson 2015. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 12:199–211.
5. Z.Bahadoran, M.Tohidi, P.Nazeri, M.Mehran, F.Azizi, P.Mirmiran. 2012. Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients:a randomized double-blind clinical trial. Int J Food Sci Nutr. 63:767–771.
6. Y.Bai, W.Cui, Y.Xin, X.Miao, M.T.Barati, C.Zhang, Q.Chen, Y.Tan, T.Cui, Y.Zheng, A.etal,. 2013. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol. 57:82–95.
7. E.Bhakkiyalakshmi, D.Sireesh, P.Rajaguru, R.Paulmurugan, K.M.Ramkumar. 2015. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes. Pharmacol Res. 91:104–114.
8. X.L.Chen, G.Dodd, C.Kunsch 2009. Sulforaphane inhibits TNF-alpha-induced activation of p38 MAP kinase and VCAM-1 and MCP-1 expression in endothelial cells. Inflamm Res. 58:513–521.
9. W.Y.Chuang, P.H.Kung, C.Y.Kuo, C.C.Wu. 2013. Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway. Thromb Haemost. 109:1120–1130.
10. W.Cui, Y.Bai, X.Miao, P.Luo, Q.Chen, Y.Tan, M.J.Rane, L.Miao, L.Cai. 2012. Prevention of diabetic nephropathy by sulforaphane:possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev. 2012:821936.
11. G.Daffu, C.H.del Pozo, K.M.O'Shea, R.Ananthakrishnan, R.Ramasamy, A.M.Schmidt. 2013. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci. 14:19891–19910.
12. R.Davis, K.P.Singh, R.Kurzrock, S.Shankar. 2009. Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep. 22:1473–1478.
13. C.G.De Souza, J.A.Sattler, A.M.De Assis, A.Rech, M.L.Perry, D.O.Souza. 2012. Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats. J Med Food. 15:795–801.
14. A.T.Dinkova-Kostova, R.V.Kostov 2012. Glucosinolates and isothiocyanates in health and disease. Trends Mol Med. 18:337–347.
15. X.L.Du, D.Edelstein, L.Rossetti, I.G.Fantus, H.Goldberg, F.Ziyadeh, J.Wu, M.Brownlee. 2000. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA. 97:12222–12226.
16. Emerging Risk Factors Collaboration, S.R.Seshasai, S.Kaptoge, A.Thompson, E.Di Angelantonio, P.Gao, N.Sarwar, P.H.Whincup, K.J.Mukamal, R.F.Gillum, I.Holme. 2011, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 364:829–841.
17. K.Fukami, T.Matsui, S.Yamagishi 2014b. Sulforaphane inhibits formation of advanced glycation end products in vitro. Diabetes Frontier Online 1:e1–e001.
18. K.Fukami, S.Yamagishi, S.Okuda 2014a. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. 20:2395–2402.
19. Y.Fukushima, H.Daida, T.Morimoto, T.Kasai, K.Miyauchi, S.Yamagishi, M.Takeuchi, T.Hiro, T.Kimura, Y.Nakagawa,. 2013. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome:the JAPAN-ACS sub-study. Cardiovasc Diabetol. 12:5.
20. K.K.Griendling, D.Sorescu, M.Ushio-Fukai 2000. NAD(P)H oxidase:role in cardiovascular biology and disease. Circ Res. 86:494–501.
21. C.E.Guerrero-Beltrán, M.Calderón-Oliver, J.Pedraza-Chaverri, Y.I.Chirino. 2012. Protective effect of sulforaphane against oxidative stress:recent advances. Exp Toxicol Pathol. 64:503–508.
22. H.P.Hammes, X.Du, D.Edelstein, T.Taguchi, T.Matsumura, Q.Ju, J.Lin, A.Bierhaus, P.Nawroth, D.Hannak,. 2003. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 9:294–299.
23. Y.Higashimoto, T.Matsui, Y.Nishino, J.Taira, H.Inoue, M.Takeuchi, S.Yamagishi. 2013. Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells. Microvasc Res. 90:64–70.
24. C.N.Hung, H.P.Huang, C.J.Wang, K.L.Liu, C.K.Lii. 2014. Sulforaphane inhibits TNF-α-induced adhesion molecule expression through the Rho A/ROCK/NF-κB signaling pathway. J Med Food. 17:1095–1102.
25. H.Hyogo, S.Yamagishi, K.Iwamoto, K.Arihiro, M.Takeuchi, T.Sato, H.Ochi, M.Nonaka, Y.Nabeshima, M.Inoue,. 2007. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 22:1112–1119.
26. International Diabetes Federation. 2013. IDF diabetes atlas. 6th ed. Brussels, Belgium:International Diabetes Federation.
27. Y.Ishibashi, T.Matsui, M.Takeuchi, S.Yamagishi. 2010. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 391:1405–1408.
28. Y.Ishibashi, T.Matsui, S.Ueda, K.Fukami, S.Yamagishi. 2014. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by upregulating protease-activated receptor-1 expression. Cardiovasc Diabetol. 13:60.
29. T.Jayakumar, W.F.Chen, W.J.Lu, D.S.Chou, G.Hsiao, C.Y.Hsu, J.R.Sheu, C.Y.Hsieh. 2013. A novel antithrombotic effect of sulforaphane via activation of platelet adenylate cyclase:ex vivo and in vivo studies. J Nutr Biochem. 24:1086–1095.
30. A.S.Jiménez-Osorio, S.González-Reyes, J.Pedraza-Chaverri 2015. Natural Nrf2 activators in diabetes. Clin Chim Acta. 448:182–192.
31. Y.Jinnouchi, S.Yamagishi, M.Takeuchi, S.Ishida, Y.Jinnouchi, J.Jinnouchi, T.Imaizumi. 2006. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med. 6:191–193.
32. M.Kajikawa, A.Nakashima, N.Fujimura, T.Maruhashi, Y.Iwamoto, A.Iwamoto, T.Matsumoto, N.Oda, T.Hidaka, Y.Kihara,. 2015. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 38:119–125.
33. B.M.Kaminski, D.Steinhilber, J.M.Stein, J.M.Stein, S.Ulrich. 2012. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol. 13:137–146.
34. J.Y.Kim, H.J.Park, S.H.Um, E.H.Sohn, B.O.Kim, E.Y.Moon, D.K.Rhee, S.Pyo. 2012. Sulforaphane suppresses vascular adhesion molecule-1 expression in TNF-α-stimulated mouse vascular smooth muscle cells:involvement of the MAPK, NF-κB and AP-1 signaling pathways. Vascul Pharmacol. 56:131–141.
35. A.M.Kivelä, P.I.Mäkinen, H.K.Jyrkkänen, E.Mella-Aho, Y.Xia, E.Kansanen, H.Leinonen, I.M.Verma, S.Ylä-Herttuala, A.L.Levonen. 2010. Sulforaphane inhibits endothelial lipase expression through NF-κB in endothelial cells. Atherosclerosis 213:122–128.
36. A.Konić-Ristić, T.Srdić-Rajić, N.Kardum, V.Aleksić-Veličković, P.A.Kroon, W.J.Hollands, P.W.Needs, N.Boyko, O.Hayran, M.Jorjadze,. 2013. Effects of bioactive-rich extracts of pomegranate, persimmon, nettle, dill, kale and Sideritis and isolated bioactives on arachidonic acid induced markers of platelet activation and aggregation. J Sci Food Agric. 93:3581–3587.
37. S.K.Ku, J.S.Bae 2014. Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. Arch Pharm Res. 37:1454–1463.
38. S.K.Ku, M.S.Han, J.S.Bae 2014. Sulforaphane inhibits endothelial protein C receptor shedding in vitro and in vivo. Vascul Pharmacol. 63:13–18.
39. C.Kunsch, R.M.Medford 1999. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 85:753–766.
40. J.S.Kwon, H.Joung, Y.S.Kim, Y.S.Shim, Y.Ahn, M.H.Jeong, H.J.Kee. 2012. Sulforaphane inhibits restenosis by suppressing inflammation and the proliferation of vascular smooth muscle cells. Atherosclerosis 225:41–49.
41. B.Li, S.Tian, X.Liu, C.He, Z.Ding, Y.Shan. 2015. Sulforaphane protected the injury of human vascular endothelial cell induced by LPC through up-regulating endogenous antioxidants and phase II enzymes. Food Funct. 6:1984–1991.
42. Y.C.Liu, C.W.Hsieh, Y.C.Weng, S.H.Chuang, C.Y.Hsieh, B.S.Wung. 2008. Sulforaphane inhibition of monocyte adhesion via the suppression of ICAM-1 and NF-kappaB is dependent upon glutathione depletion in endothelial cells. Vascul Pharmacol. 48:54–61.
43. L.Loukine, C.Waters, B.C.Choi, J.Ellison. 2012. Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. Popul Health Metr. 10:7.
44. S.Maeda, T.Matsui, A.Ojima, M.Takeuchi, S.Yamagishi. 2014. Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products. Nutr Res. 34:807–813.
45. S.Medina, R.Domínguez-Perles, D.A.Moreno, C.García-Viguera, F.Ferreres, J.I.Gil, Á.Gil-Izquierdo. 2015. The intake of broccoli sprouts modulates the inflammatory and vascular prostanoids but not the oxidative stress-related isoprostanes in healthy humans. Food Chem. 173:1187–1194.
46. K.Nakamura, S.Yamagishi, H.Adachi, T.Matsui, Y.Kurita-Nakamura, M.Takeuchi, H.Inoue, T.Imaizumi. 2008. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev. 24:109–114.
47. K.Nakamura, S.Yamagishi, T.Matsui, T.Yoshida, K.Takenaka, Y.Jinnouchi, Y.Yoshida, S.Ueda, H.Adachi, T.Imaizumi. 2007. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol. 170:2159–2170.
48. P.Nallasamy, H.Si, P.V.Babu, D.Pan, Y.Fu, E.A.Brooke, H.Shah, W.Zhen, H.Zhu, D.Liu,. 2014. Sulforaphane reduces vascular inflammation in mice and prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway. J Nutr Biochem. 25:824–833.
49. D.M.Nathan, DCCT/EDIC Research Group. 2014. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years:overview. Diabetes Care 37:9–16.
50. G.Negi, A.Kumar, S.S.Sharma 2011. Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr Neurovasc Res. 8:294–304.
51. T.Nishikawa, D.Edelstein, X.L.Du, S.Yamagishi, T.Matsumura, Y.Kaneda, M.A.Yorek, D.Beebe, P.J.Oates, H.P.Hammes,. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790.
52. T.Nishikawa, N.H.Tsuno, Y.Okaji, E.Sunami, Y.Shuno, K.Sasaki, K.Hongo, M.Kaneko, M.Hiyoshi, K.Kawai,. 2010. The inhibition of autophagy potentiates anti-angiogenic effects of sulforaphane by inducing apoptosis. Angiogenesis 13:227–238.
53. T.Nishikawa, N.H.Tsuno, T.Tsuchiya, S.Yoneyama, J.Yamada, Y.Shuno, Y.Okaji, J.Tanaka, J.Kitayama, K.Takahashi,. 2009. Sulforaphane stimulates activation of proapoptotic protein bax leading to apoptosis of endothelial progenitor cells. Ann Surg Oncol. 16:534–543.
54. C.H.Oh, J.I.Shin, S.J.Mo, S.J.Yun, S.H.Kim, Y.H.Rhee. 2013. Antiplatelet activity of L-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2. Blood Coagul Fibrinol. 24:498–504.
55. A.Ojima, Y.Ishibashi, T.Matsui, S.Maeda, Y.Nishino, M.Takeuchi, K.Fukami, S.Yamagishi. 2013. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol. 182:132–141.
56. A.Orlidge, P.A.D'Amore 1987. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol. 105:1455–1462.
57. A.Raucci, S.Cugusi, A.Antonelli, S.M.Barabino, L.Monti, A.Bierhaus, K.Reiss, P.Saftig, M.E.Bianchi. 2008. Soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22:3716–3727.
58. E.T.Rhodes, L.A.Prosser, T.J.Hoerger, T.Lieu, D.S.Ludwig, L.M.Laffel. 2012. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. Diabet Med. 29:453–463.
59. Y.Shan, N.Lin, X.Yang, J.Tan, R.Zhao, S.Dong, S.Wang. 2012. Sulphoraphane inhibited the expressions of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 through MyD88-dependent toll-like receptor-4 pathway in cultured endothelial cells. Nutr Metab Cardiovasc Dis. 22:215–222.
60. Y.Shan, R.Zhao, W.Geng, N.Lin, X.Wang, X.Du, S.Wang. 2010. Protective effect of sulforaphane on human vascular endothelial cells against lipopolysaccharide-induced inflammatory damage. Cardiovasc Toxicol. 10:139–145.
61. G.Shang, X.Tang, P.Gao, F.Guo, H.Liu, Z.Zhao, Q.Chen, T.Jiang, N.Zhang, H.Li. 2015. Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway. J Nutr Biochem. 26:596–606.
62. K.C.Sourris, J.M.Forbes 2009. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr Drug Targets. 10:42–50.
63. N.Tahara, A.Tahara, A.Honda, Y.Nitta, N.Kodama, S.Yamagishi, T.Imaizumi. 2014. Molecular imaging of vascular inflammation. Curr Pharm Des. 20:2439–2447.
64. N.Tahara, S.Yamagishi, T.Matsui, M.Takeuchi, Y.Nitta, N.Kodama, M.Mizoguchi, T.Imaizumi. 2012a. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther. 30:42–48.
65. N.Tahara, S.Yamagishi, M.Takeuchi, A.Honda, A.Tahara, Y.Nitta, N.Kodama, M.Mizoguchi, H.Kaida, M.Ishibashi,. 2012b. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 35:2618–2625.
66. N.Tahara, S.I.Yamagishi, N.Kodama, A.Tahara, A.Honda, Y.Nitta, S.Igata, T.Matsui, M.Takeuchi, H.Kaida,. 2015. Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT. J Clin Endocrinol Metab. 100:E739–E747.
67. K.Takenaka, S.Yamagishi, T.Matsui, K.Nakamura, T.Imaizumi. 2006. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res. 3:73–77.
68. M.Takeuchi, S.Yamagishi 2009. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis. 16:845–858.
69. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:977–986.
70. S.M.Tortorella, S.G.Royce, P.V.Licciardi, T.C.Karagiannis. 2015. Dietary sulforaphane in cancer chemoprevention:the role of epigenetic regulation and HDAC inhibition. Antioxid Redox Signal. 22:1382–1424.
71. T.C.Turin, Y.Murakami, K.Miura, N.Rumana, A.Kadota, T.Ohkubo, T.Okamura, A.Okayama, H.Ueshima; NIPPON DATA 80 Group. 2012. Diabetes and life expectancy among Japanese-NIPPON DATA80. Diabetes Res Clin Pract. 96:e18–e22.
72. S.Ueda, S.Yamagishi, T.Matsui, Y.Noda, S.Ueda, Y.Jinnouchi, K.Sasaki, M.Takeuchi, T.Imaizumi. 2012. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther. 30:249–254.
73. UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853.
74. G.V.Velmurugan, N.R.Sundaresan, M.P.Gupta, M.P.Gupta, C.White. 2013. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res. 100:143–150.
75. A.M.Vincent, K.Kato, L.L.McLean, M.E.Soules, E.L.Feldman. 2009. Sensory neurons and Schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid Redox Signal. 11:425–438.
76. H.Vlassara, J.Uribarri 2014. Advanced glycation end products (AGE) and diabetes:cause, effect, or both? Curr Diab Rep. 14:453.
77. Y.Wang, Z.Zhang, W.Sun, Y.Tan, Y.Liu, Y.Zheng, Q.Liu, L.Cai, J.Sun. 2014. Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function. Oxid Med Cell Longev. 2014:123963.
78. Writing Group for the DCCT/EDIC Research Group. 2015. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 313:45–53.
79. J.Xuj, S.R.Kulkarni, A.C.Donepudi, V.R.More, A.L.Slitt. 2012. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes 61:3208–3218.
80. M.Xue, Q.Qian, A.Adaikalakoteswari, N.Rabbani, R.Babaei-Jadidi, P.J.Thornalley. 2008. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 57:2809–2817.
81. S.Yamagishi 2011. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 12:2096–2102.
82. S.Yamagishi 2012. Potential clinical utility of advanced glycation end product cross-link breakers in age-and diabetes-associated disorders. Rejuvenation Res. 15:564–572.
83. S.Yamagishi, H.Adachi, M.Takeuchi, M.Enomoto, K.Furuki, T.Matsui, K.Nakamura, T.Imaizumi. 2007. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res. 39:845–848.
84. S.Yamagishi, S.Amano, Y.Inagaki, T.Okamoto, M.Takeuchi, Z.Makita. 2002. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med. 8:546–550.
85. S.Yamagishi, H.Fujimori, H.Yonekura, Y.Yamamoto, H.Yamamoto. 1998. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 41:1435–1441.
86. S.Yamagishi, T.Imaizumi 2005. Diabetic vascular complications:pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 11:2279–2299.
87. S.Yamagishi, K.Kobayashi, H.Yamamoto 1993. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. Biochem Biophys Res Commun. 190:418–425.
88. S.I.Yamagishi, T.Matsui 2010a. Anti-atherothrombogenic properties of PEDF. Curr Mol Med. 10:284–291.
89. S.Yamagishi, T.Matsui 2010b. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed). 2:1184–1195.
90. S.Yamagishi, T.Matsui 2015. Protective role of sodium-glucose cotransporter 2 (SGLT2) inhibition against vascular complications in diabetes. Rejuvenation Res. doi:10.1089/rej.2015.1738.
91. S.Yamagishi, T.Matsui, K.Fukami 2015a. Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res. 18:48–56.
92. S.Yamagishi, T.Matsui, K.Takenaka, K.Nakamura, M.Takeuchi, H.Inoue. 2009. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev. 25:266–271.
93. S.Yamagishi, K.Nakamura, T.Matsui 2008. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem. 15:172–177.
94. S.Yamagishi, Y.Nishino, A.Ojima, T.Matsui, H.Nishi. 2015b. Oral consumption of sulforaphane precursor-rich broccoli supersprouts decreases serum levels of advanced glycation end products in humans. Diabetes Frontier Online 2:e1–e011.
95. K.Yoh, A.Hirayama, K.Ishizaki, A.Yamada, M.Takeuchi, S.Yamagishi, N.Morito, T.Nakano, M.Ojima, H.Shimohata,. 2008. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 13:1159–1170.
96. S.H.Yoo, Y.Lim, S.J.Kim, K.D.Yoo, H.S.Yoo, J.T.Hong, M.Y.Lee, Y.P.Yun. 2013. Sulforaphane inhibits PDGF-induced proliferation of rat aortic vascular smooth muscle cell by up-regulation of p53 leading to G1/S cell cycle arrest. Vascul Pharmacol. 59:44–51.
97. M.Zakkar, K.Van der Heiden, A.Luong le, H.Chaudhury, S.Cuhlmann, S.S.Hamdulay, R.Krams, I.Edirisinghe, I.Rahman, H.Carlsen,. 2009. Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol. 29:1851–1857.
98. Z.Zhang, S.Wang, S.Zhou, X.Yan, Y.Wang, J.Chen, N.Mellen, M.Kong, J.Gu, Y.Tan,. 2014. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. J Mol Cell Cardiol. 77:42–52.
99. X.D.Zhao, Y.T.Zhou, X.J.Lu 2013. Sulforaphane enhances the activity of the Nrf2-ARE pathway and attenuates inflammation in OxyHb-induced rat vascular smooth muscle cells. Inflamm Res. 62:857–863.
100. H.Zheng, S.A.Whitman, W.Wu, G.T.Wondrak, P.K.Wong, D.Fang, D.D.Zhang. 2011. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60:3055–3066.
101. H.Zhu, Z.Jia, J.S.Strobl, M.Ehrich, H.P.Misra, Y.Li. 2008. Potent induction of total cellular and mitochondrial antioxidants and phase 2 enzymes by cruciferous sulphoraphane in rat aortic smooth muscle cells:cytoprotection against oxidative and electrophilic stress. Cardiovasc Toxicol. 8:115–125.